Acute cellular and antibody-mediated allograft rejection

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 3, 2013, Pages 320-335

  McManigle, William ^a   Pavlisko, Elizabethn ^a   Martinu, Tereza ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

acute rejection; antibody mediated rejection; humoral rejection; lung transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; COMPLEMENT; CYCLOSPORIN; ECULIZUMAB; EVEROLIMUS; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ARTICLE; BRONCHOSCOPY; CHRONIC GRAFT REJECTION; CLINICAL FEATURE; DEATH; GRAFT DYSFUNCTION; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG INJURY; LUNG PARENCHYMA; LUNG TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; NEPHROTOXICITY; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; RISK FACTOR; TRANSBRONCHIAL BIOPSY;

ALLOGRAFTS; ANIMALS; ANTIBODIES; BRONCHOSCOPY; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; LUNG TRANSPLANTATION; RISK FACTORS; SURVIVAL RATE;

EID: 84879948111     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1348471     Document Type: Article

References (173)

1. Snyder L. D., Palmer S. M. Immune mechanisms of lung allograft rejection. SeminRespirCrit Care Med: 2006; 27 5 534 543
2. Abbas A. K., Lichtman A. H., Pillai S. Cellular and Molecular Immunology. 6th ed. Philadelphia, PA Elsevier: 2010
3. Valujskikh A., Baldwin W. M. III, Fairchild R. L. Recent progress and new perspectives in studying T cell responses to allografts. Am J Transplant: 2010; 10 5 1117 1125
4. Gelman A. E., Li W., Richardson S. B., et al. Cutting edge: acute lung allograft rejection is independent of secondary lymphoid organs. J Immunol: 2009; 182 7 3969 3973
5. Sato M., Hirayama S., Hwang D. M., et al. The role of intrapulmonary de novo lymphoid tissue in obliterative bronchiolitis after lung transplantation. J Immunol: 2009; 182 11 7307 7316
6. Csencsits K. L., Bishop D. K. Contrasting alloreactive CD4+ and CD8+ T cells: there's more to it than MHC restriction. Am J Transplant: 2003; 3 2 107 115
7. Burlingham W. J., Love R. B., Jankowska-Gan E., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest: 2007; 117 11 3498 3506
8. Bharat A., Fields R. C., Trulock E. P., Patterson G. A., Mohanakumar T. Induction of IL-10 suppressors in lung transplant patients by CD4+25+ regulatory T cells through CTLA-4 signaling. J Immunol: 2006; 177 8 5631 5638
9. Braun R. K., Molitor-Dart M., Wigfield C., et al. Transfer of tolerance to collagen type V suppresses T-helper-cell-17 lymphocyte-mediated acute lung transplant rejection. Transplantation: 2009; 88 12 1341 1348
10. Bharat A., Fields R. C., Steward N., Trulock E. P., Patterson G. A., Mohanakumar T. CD4+25+ regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant: 2006; 6 8 1799 1808
11. De Vito Dabbs A., Hoffman L. A., Iacono A. T., Zullo T. G., McCurry K. R., Dauber J. H. Are symptom reports useful for differentiating between acute rejection and pulmonary infection after lung transplantation? Heart Lung: 2004; 33 6 372 380
12. Gotway M. B., Dawn S. K., Sellami D., et al. Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis. Radiology: 2001; 221 1 207 212
13. Ng Y. L., Paul N., Patsios D., et al. Imaging of lung transplantation: review. AJR Am J Roentgenol: 2009; 192 (3, Suppl): S1 S13, quiz S14-S19
14. Van Muylem A., Mélot C., Antoine M., Knoop C., Estenne M. Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation. Thorax: 1997; 52 7 643 647
15. Gordon I. O., Bhorade S., Vigneswaran W. T., Garrity E. R., Husain A. N. SaLUTaRy: survey of lung transplant rejection. J Heart Lung Transplant: 2012; 31 9 972 979
16. Hasegawa T., Iacono A. T., Yousem S. A. The anatomic distribution of acute cellular rejection in the allograft lung. Ann Thorac Surg: 2000; 69 5 1529 1531
17. Stewart S., Fishbein M. C., Snell G. I., et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant: 2007; 26 12 1229 1242
18. Vanaudenaerde B. M., Dupont L. J., Wuyts W. A., et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J: 2006; 27 4 779 787
19. Bhorade S. M., Yu A., Vigneswaran W. T., Alex C. G., Garrity E. R. Elevation of interleukin-15 protein expression in bronchoalveolar fluid in acute lung allograft rejection. Chest: 2007; 131 2 533 538
20. Ross D. J., Moudgil A., Bagga A., et al. Lung allograft dysfunction correlates with gamma-interferon gene expression in bronchoalveolar lavage. J Heart Lung Transplant: 1999; 18 7 627 636
21. Patel J. M., Hu H., Lu L., et al. Thioredoxin as a biomarker for graft rejection in lung transplant recipients. Biomarkers: 2008; 13 5 486 495
22. Vos R., Vanaudenaerde B. M., Verleden S. E., et al. Bronchoalveolar lavage neutrophilia in acute lung allograft rejection and lymphocytic bronchiolitis. J Heart Lung Transplant: 2010; 29 11 1259 1269
23. Gregson A. L., Hoji A., Saggar R., et al. Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection. Transplantation: 2008; 85 7 1056 1059
24. Meehan A. C., Sullivan L. C., Mifsud N. A., et al. Natural killer cell activation in the lung allograft early posttransplantation. Transplantation: 2010; 89 6 756 763
25. Madsen C. B., Norgaard A., Iversen M., Ryder L. P. Elevated mRNA levels of CTLA-4, FoxP3, and granzyme B in BAL, but not in blood, during acute rejection of lung allografts. Transpl Immunol: 2010; 24 1 26 32
26. San Segundo D., Brunet M., Ballesteros M. A., et al. Prospective study of biomarkers of immune response in lung transplant recipients. Transplant Proc: 2012; 44 9 2666 2668
27. Patil J., Lande J. D., Li N., Berryman T. R., King R. A., Hertz M. I. Bronchoalveolar lavage cell gene expression in acute lung rejection: development of a diagnostic classifier. Transplantation: 2008; 85 2 224 231
28. Chambers D. C., Hodge S., Hodge G., et al. A novel approach to the assessment of lymphocytic bronchiolitis after lung transplantation- transbronchial brush. J Heart Lung Transplant: 2011; 30 5 544 551
29. Hodge G., Hodge S., Chambers D. C., Reynolds P. N., Holmes M. Increased expression of graft intraepithelial T-cell pro-inflammatory cytokines compared with native lung during episodes of acute rejection. J Heart Lung Transplant: 2012; 31 5 538 544
30. Kowalski R. J., Post D. R., Mannon R. B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation: 2006; 82 5 663 668
31. Bhorade S. M., Janata K., Vigneswaran W. T., Alex C. G., Garrity E. R. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant: 2008; 27 9 990 994
32. Husain S., Raza K., Pilewski J. M., et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation: 2009; 87 12 1852 1857
33. Shino M. Y., Weigt S. S., Saggar R., et al. Usefulness of immune monitoring in lung transplantation using adenosine triphosphate production in activated lymphocytes. J Heart Lung Transplant: 2012; 31 9 996 1002
34. Chakinala M. M., Ritter J., Gage B. F., et al. Reliability for grading acute rejection and airway inflammation after lung transplantation. J Heart Lung Transplant: 2005; 24 6 652 657
35. Stephenson A., Flint J., English J., et al. Interpretation of transbronchial lung biopsies from lung transplant recipients: inter- and intraobserver agreement. Can Respir J: 2005; 12 2 75 77
36. Colombat M., Groussard O., Lautrette A., et al. Analysis of the different histologic lesions observed in transbronchial biopsy for the diagnosis of acute rejection. Clinicopathologic correlations during the first 6 months after lung transplantation. Hum Pathol: 2005; 36 4 387 394
37. Arcasoy S. M., Berry G., Marboe C. C., et al. Pathologic interpretation of transbronchial biopsy for acute rejection of lung allograft is highly variable. Am J Transplant: 2011; 11 2 320 328
38. Hasegawa T., Iacono A., Yousem S. A. The significance of bronchus-associated lymphoid tissue in human lung transplantation: is there an association with acute and chronic rejection? Transplantation: 1999; 67 3 381 385
39. Shenoy K. V., Solomides C., Cordova F., Rogers T. J., Ciccolella D., Criner G. J. Low CD4/CD8 ratio in bronchus-associated lymphoid tissue is associated with lung allograft rejection. J Transplant: 2012; 2012 928081
40. Christie J. D., Edwards L. B., Kucheryavaya A. Y., et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report-2011. J Heart Lung Transplant: 2011; 30 10 1104 1122
41. Burton C. M., Iversen M., Carlsen J., et al. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1. J Heart Lung Transplant: 2009; 28 9 888 893
42. Sharples L. D., McNeil K., Stewart S., Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant: 2002; 21 2 271 281
43. Girgis R. E., Tu I., Berry G. J., et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant: 1996; 15 12 1200 1208
44. Bando K., Paradis I. L., Similo S., et al. Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg: 1995; 110 1 4 13, discussion 13-14
45. Kim D. W., Dacic S., Iacono A., Grgurich W., Yousem S. A. Significance of a solitary perivascular mononuclear infiltrate in lung allograft recipients with mild acute cellular rejection. J Heart Lung Transplant: 2005; 24 2 152 155
46. Burton C. M., Iversen M., Scheike T., Carlsen J., Andersen C. B. Minimal acute cellular rejection remains prevalent up to 2 years after lung transplantation: a retrospective analysis of 2697 transbronchial biopsies. Transplantation: 2008; 85 4 547 553
47. DeVito Dabbs A., Hoffman L. A., Iacono A. T., et al. Pattern and predictors of early rejection after lung transplantation. Am J Crit Care: 2003; 12 6 497 507
48. Yousem S. A. The potential role of mast cells in lung allograft rejection. Hum Pathol: 1997; 28 2 179 182
49. Scholma J., Slebos D. J., Boezen H. M., et al. Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med: 2000; 162 6 2221 2225
50. Yousem S. A., Martin T., Paradis I. L., Keenan R., Griffith B. P. Can immunohistological analysis of transbronchial biopsy specimens predict responder status in early acute rejection of lung allografts? Hum Pathol: 1994; 25 5 525 529
51. Glanville A. R., Aboyoun C. L., Havryk A., Plit M., Rainer S., Malouf M. A. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med: 2008; 177 9 1033 1040
52. Husain A. N., Siddiqui M. T., Montoya A., Chandrasekhar A. J., Garrity E. R. Post-lung transplant biopsies: an 8-year Loyola experience. Mod Pathol: 1996; 9 2 126 132
53. Irani S., Gaspert A., Vogt P., et al. Inflammation patterns in allogeneic and autologous airway tissue of lung transplant recipients. Am J Transplant: 2005; 5 10 2456 2463
54. Ward C., Snell G. I., Orsida B., Zheng L., Williams T. J., Walters E. H. Airway versus transbronchial biopsy and BAL in lung transplant recipients: different but complementary. Eur Respir J: 1997; 10 12 2876 2880
55. Xu X., Golden J. A., Dolganov G., et al. Transcript signatures of lymphocytic bronchitis in lung allograft biopsy specimens. J Heart Lung Transplant: 2005; 24 8 1055 1066
56. Greenland J. R., Jones K. D., Hays S. R., et al. Association of Large-Airway Lymphocytic Bronchitis with Bronchiolitis Obliterans Syndrome. Am J Respir Crit Care Med: 2013; 187 4 417 423
57. Davis W. A., Finlen Copeland C. A., Todd J. L., Snyder L. D., Martissa J. A., Palmer S. M. Spirometrically significant acute rejection increases the risk for BOS and death after lung transplantation. Am J Transplant: 2012; 12 3 745 752
58. Schulman L. L., Weinberg A. D., McGregor C., Galantowicz M. E., Suciu-Foca N. M., Itescu S. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med: 1998; 157 6, Pt 1 1833 1837
59. Quantz M. A., Bennett L. E., Meyer D. M., Novick R. J. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant: 2000; 19 5 473 479
60. Wisser W., Wekerle T., Zlabinger G., et al. Influence of human leukocyte antigen matching on long-term outcome after lung transplantation. J Heart Lung Transplant: 1996; 15 12 1209 1216
61. Mangi A. A., Mason D. P., Nowicki E. R., et al. Predictors of acute rejection after lung transplantation. Ann Thorac Surg: 2011; 91 6 1754 1762
62. Peltz M., Edwards L. B., Jessen M. E., Torres F., Meyer D. M. HLA mismatches influence lung transplant recipient survival, bronchiolitis obliterans and rejection: implications for donor lung allocation. J Heart Lung Transplant: 2011; 30 4 426 434
63. Opelz G., Süsal C., Ruhenstroth A., Döhler B. Impact of HLA compatibility on lung transplant survival and evidence for an HLA restriction phenomenon: a collaborative transplant study report. Transplantation: 2010; 90 8 912 917
64. Palmer S. M., Baz M. A., Sanders L., et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation: 2001; 71 12 1772 1776
65. Treede H., Glanville A. R., Klepetko W., et al. European and Australian Investigators in Lung Transplantation Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant: 2012; 31 8 797 804
66. Lischke R., Simonek J., Davidová R., et al. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. Transplant Proc: 2007; 39 1 205 212
67. Gullestad L., Mortensen S. A., Eiskjær H., et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation: 2010; 90 12 1581 1589
68. Bhorade S., Ahya V. N., Baz M. A., et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med: 2011; 183 3 379 387
69. Shyu S., Dew M. A., Pilewski J. M., et al. Five-year outcomes with alemtuzumab induction after lung transplantation. J Heart Lung Transplant: 2011; 30 7 743 754
70. Ahya V. N., Douglas L. P., Andreadis C., et al. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant: 2007; 26 8 839 844
71. Zheng H. X., Burckart G. J., McCurry K., et al. Interleukin-10 production genotype protects against acute persistent rejection after lung transplantation. J Heart Lung Transplant: 2004; 23 5 541 546
72. Palmer S. M., Burch L. H., Trindade A. J., et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med: 2005; 171 7 780 785
73. Girnita D. M., Webber S. A., Zeevi A. Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation. Clin Lab Med: 2008; 28 3 423 440, vi
74. Colobran R., Casamitjana N., Roman A., et al. Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation. Genes Immun: 2009; 10 3 254 259
75. Palmer S. M., Klimecki W., Yu L., et al. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant: 2007; 7 3 693 699
76. Zheng H. X., Zeevi A., McCurry K., et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol: 2005; 14 1 37 42
77. Gutierrez C., Al-Faifi S., Chaparro C., et al. The effect of recipient's age on lung transplant outcome. Am J Transplant: 2007; 7 5 1271 1277
78. Mahidhara R., Bastani S., Ross D. J., et al. Lung transplantation in older patients? J Thorac Cardiovasc Surg: 2008; 135 2 412 420
79. Scott J. P., Whitehead B., de Leval M., et al. Paediatric incidence of acute rejection and obliterative bronchiolitis: a comparison with adults. Transpl Int: 1994; 7 01 S404 S406
80. Ibrahim J. E., Sweet S. C., Flippin M., et al. Rejection is reduced in thoracic organ recipients when transplanted in the first year of life. J Heart Lung Transplant: 2002; 21 3 311 318
81. Hartwig M. G., Appel J. Z., Li B., et al. Chronic aspiration of gastric fluid accelerates pulmonary allograft dysfunction in a rat model of lung transplantation. J Thorac Cardiovasc Surg: 2006; 131 1 209 217
82. Shah N., Force S. D., Mitchell P. O., et al. Gastroesophageal reflux disease is associated with an increased rate of acute rejection in lung transplant allografts. Transplant Proc: 2010; 42 7 2702 2706
83. Murthy S. C., Nowicki E. R., Mason D. P., et al. Pretransplant gastroesophageal reflux compromises early outcomes after lung transplantation. J Thorac Cardiovasc Surg: 2011; 142 1 47 52, e3
84. Fisichella P. M., Davis C. S., Lundberg P. W., et al. The protective role of laparoscopic antireflux surgery against aspiration of pepsin after lung transplantation. Surgery: 2011; 150 4 598 606
85. Verleden S. E., Scheers H., Nawrot T. S., et al. Lymphocytic bronchiolitis after lung transplantation is associated with daily changes in air pollution. Am J Transplant: 2012; 12 7 1831 1838
86. Kumar D., Husain S., Chen M. H., et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation: 2010; 89 8 1028 1033
87. Kumar D., Erdman D., Keshavjee S., et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant: 2005; 5 8 2031 2036
88. Vilchez R. A., Dauber J., McCurry K., Iacono A., Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant: 2003; 3 2 116 120
89. Garantziotis S., Howell D. N., McAdams H. P., Davis R. D., Henshaw N. G., Palmer S. M. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest: 2001; 119 4 1277 1280
90. Khalifah A. P., Hachem R. R., Chakinala M. M., et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med: 2004; 170 2 181 187
91. Larcher C., Geltner C., Fischer H., Nachbaur D., Müller L. C., Huemer H. P. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J Heart Lung Transplant: 2005; 24 11 1891 1901
92. Soccal P. M., Aubert J. D., Bridevaux P. O., et al. Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients. Clin Infect Dis: 2010; 51 2 163 170
93. Vu D. L., Bridevaux P. O., Aubert J. D., Soccal P. M., Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant: 2011; 11 5 1071 1078
94. Weigt S. S., Derhovanessian A., Liao E., et al. CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction. Am J Transplant: 2012; 12 2 477 484
95. Costa C., Delsedime L., Solidoro P., et al. Herpesviruses detection by quantitative real-time polymerase chain reaction in bronchoalveolar lavage and transbronchial biopsy in lung transplant: viral infections and histopathological correlation. Transplant Proc: 2010; 42 4 1270 1274
96. Bergallo M., Costa C., Terlizzi M. E., et al. Quantitative detection of the new polyomaviruses KI, WU and Merkel cell virus in transbronchial biopsies from lung transplant recipients. J Clin Pathol: 2010; 63 8 722 725
97. Astegiano S., Bergallo M., Solidoro P., et al. Prevalence and clinical impact of polyomaviruses KI and WU in lung transplant recipients. Transplant Proc: 2010; 42 4 1275 1278
98. Palmer S. M., Limaye A. P., Banks M., et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med: 2010; 152 12 761 769
99. Yamamoto S., Nava R. G., Zhu J., et al. Cutting edge: Pseudomonas aeruginosa abolishes established lung transplant tolerance by stimulating B7 expression on neutrophils. J Immunol: 2012; 189 9 4221 4225
100. Shields R. K., Clancy C. J., Minces L. R., et al. Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes. J Heart Lung Transplant: 2012; 31 11 1199 1206
101. Glanville A. R., Gencay M., Tamm M., et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant: 2005; 24 2 131 136
102. Clelland C., Higenbottam T., Stewart S., et al. Bronchoalveolar lavage and transbronchial lung biopsy during acute rejection and infection in heart-lung transplant patients. Studies of cell counts, lymphocyte phenotypes, and expression of HLA-DR and interleukin-2 receptor. Am Rev Respir Dis: 1993; 147 6 Pt 1 1386 1392
103. Lau C. L., Palmer S. M., D'Amico T. A., Tapson V. F., Davis R. D. Lung transplantation at Duke University Medical Center. Clin Transpl: 1998; 327 340
104. Fuehner T., Simon A., Dierich M., et al. Indicators for steroid response in biopsy proven acute graft rejection after lung transplantation. Respir Med: 2009; 103 8 1114 1121
105. Vitulo P., Oggionni T., Cascina A., et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant: 2002; 21 4 435 439
106. Sarahrudi K., Estenne M., Corris P., et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg: 2004; 127 4 1126 1132
107. Shennib H., Massard G., Reynaud M., Noirclerc M. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. J Heart Lung Transplant: 1994; 13 3 514 519
108. Reams B. D., Musselwhite L. W., Zaas D. W., et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant: 2007; 7 12 2802 2808
109. Keenan R. J., Iacono A., Dauber J. H., et al. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg: 1997; 113 2 335 340, discussion 340-341
110. Iacono A., Dauber J., Keenan R., et al. Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation: 1997; 64 2 263 269
111. Dall'Amico R., Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. Transfus Apheresis Sci: 2002; 26 3 197 204
112. Valentine V. G., Robbins R. C., Wehner J. H., Patel H. R., Berry G. J., Theodore J. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest: 1996; 109 5 1184 1189
113. Tait B. D., Süsal C., Gebel H. M., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation: 2013; 95 1 19 47
114. Colvin R. B., Smith R. N. Antibody-mediated organ-allograft rejection. Nat Rev Immunol: 2005; 5 10 807 817
115. Stegall M. D., Chedid M. F., Cornell L. D. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol: 2012; 8 11 670 678
116. Takenaka M., Subramanian V., Tiriveedhi V., et al. Complement activation is not required for obliterative airway disease induced by antibodies to major histocompatibility complex class I: Implications for chronic lung rejection. J Heart Lung Transplant: 2012; 31 11 1214 1222
117. Campo-Cañaveral de la Cruz J. L., Naranjo J. M., Salas C., Varela de Ugarte A. Fulminant hyperacute rejection after unilateral lung transplantation. Eur J Cardiothorac Surg: 2012; 42 2 373 375
118. Bittner H. B., Dunitz J., Hertz M., Bolman M. R. III, Park S. J. Hyperacute rejection in single lung transplantation-case report of successful management by means of plasmapheresis and antithymocyte globulin treatment. Transplantation: 2001; 71 5 649 651
119. Neumann J., Tarrasconi H., Bortolotto A., et al. Acute humoral rejection in a lung recipient: reversion with bortezomib. Transplantation: 2010; 89 1 125 126
120. Stuckey L. J., Kamoun M., Chan K. M. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Ann Pharmacother: 2012; 46 1 e2
121. Campion E. W. A death at Duke. N Engl J Med: 2003; 348 12 1083 1084
122. Pierson R. N. III, Loyd J. E., Goodwin A., et al. Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy. Transplantation: 2002; 74 1 79 84
123. Patel M., Carby M., Rice A., Cummins D., Banner N. R. Medium-term outcome of an ABO incompatible lung transplant. Am J Transplant: 2010; 10 3 702 703
124. Strüber M., Warnecke G., Hafer C., et al. Intentional ABO-incompatible lung transplantation. Am J Transplant: 2008; 8 11 2476 2478
125. Yousem S. A., Zeevi A. The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies. Am J Surg Pathol: 2012; 36 7 987 992
126. Berry G., Burke M., Andersen C., et al. Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant: 2013; 32 1 14 21
127. Astor T. L., Weill D., Cool C., Teitelbaum I., Schwarz M. I., Zamora M. R. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. J Heart Lung Transplant: 2005; 24 12 2091 2097
128. Khan M. A., Nicolls M. R. Complement-mediated microvascular injury leads to chronic rejection. Adv Exp Med Biol: 2013; 735 233 246
129. Jaramillo A., Smith C. R., Maruyama T., Zhang L., Patterson G. A., Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol: 2003; 64 5 521 529
130. Saini D., Angaswamy N., Tiriveedhi V., et al. Synergistic effect of antibodies to human leukocyte antigens and defensins in pathogenesis of bronchiolitis obliterans syndrome after human lung transplantation. J Heart Lung Transplant: 2010; 29 12 1330 1336
131. Maruyama T., Jaramillo A., Narayanan K., Higuchi T., Mohanakumar T. Induction of obliterative airway disease by anti-HLA class I antibodies. Am J Transplant: 2005; 5 9 2126 2134
132. Fukami N., Ramachandran S., Saini D., et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol: 2009; 182 1 309 318
133. Goers T. A., Ramachandran S., Aloush A., Trulock E., Patterson G. A., Mohanakumar T. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol: 2008; 180 7 4487 4494
134. Iwata T., Philipovskiy A., Fisher A. J., et al. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol: 2008; 181 8 5738 5747
135. Tiriveedhi V., Angaswamy N., Weber J., Mohanakumar T. Lipid raft facilitated ligation of K-alpha1-tubulin by specific antibodies on epithelial cells: role in pathogenesis of chronic rejection following human lung transplantation. Biochem Biophys Res Commun: 2010; 399 2 251 255
136. McKenna R. M., Takemoto S. K., Terasaki P. I. Anti-HLA antibodies after solid organ transplantation. Transplantation: 2000; 69 3 319 326
137. Pei R., Lee J. H., Shih N. J., Chen M., Terasaki P. I. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation: 2003; 75 1 43 49
138. Cecka J. M. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant: 2010; 10 1 26 29
139. Liu C., Wetter L., Pang S., Phelan D. L., Mohanakumar T., Morris G. P. Cutoff values and data handling for solid-phase testing for antibodies to HLA: effects on listing unacceptable antigens for thoracic organ transplantation. Hum Immunol: 2012; 73 6 597 604
140. Yabu J. M., Higgins J. P., Chen G., Sequeira F., Busque S., Tyan D. B. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation: 2011; 91 3 342 347
141. Chin C., Chen G., Sequeria F., et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant: 2011; 30 2 158 163
142. Appel J. Z. III, Hartwig M. G., Davis R. D., Reinsmoen N. L. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol: 2005; 66 4 378 386
143. Hachem R. R., Yusen R. D., Meyers B. F., et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant: 2010; 29 9 973 980
144. Appel J. Z. III, Hartwig M. G., Cantu E. III, Palmer S. M., Reinsmoen N. L., Davis R. D. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation: 2006; 81 7 1049 1057
145. Taylor C. J., Smith S. I., Morgan C. H., et al. Selective omission of the donor cross-match before renal transplantation: efficacy, safety and effects on cold storage time. Transplantation: 2000; 69 5 719 723
146. Lobo L. J., Aris R. M., Schmitz J., Neuringer I. P. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant: 2013; 32 1 70 77
147. Snyder L. D., Wang Z., Chen D. F., et al. Implications for human leukocyte antigen antibodies after lung transplantation: a 10 year experience in 441 patients. Chest: 2013
148. Girnita A. L., McCurry K. R., Iacono A. T., et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant: 2004; 23 10 1135 1141
149. Girnita A. L., Duquesnoy R., Yousem S. A., et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant: 2005; 5 1 131 138
150. Palmer S. M., Davis R. D., Hadjiliadis D., et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation: 2002; 74 6 799 804
151. Hadjiliadis D., Chaparro C., Reinsmoen N. L., et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant: 2005; 24 (7, Suppl): S249 S254
152. Shah A. S., Nwakanma L., Simpkins C., Williams J., Chang D. C., Conte J. V. Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients. Ann Thorac Surg: 2008; 85 6 1919 1924
153. Saini D., Weber J., Ramachandran S., et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant: 2011; 30 6 624 631
154. Smith J. D., Crisp S. J., Dunn M. J., Pomerance A., Yacoub M. H., Rose M. L. Pre-transplant anti-epithelial cell antibodies and graft failure after single lung transplantation. Transpl Immunol: 1995; 3 1 68 73
155. Magro C. M., Klinger D. M., Adams P. W., et al. Evidence that humoral allograft rejection in lung transplant patients is not histocompatibility antigen-related. Am J Transplant: 2003; 3 10 1264 1272
156. Angaswamy N., Saini D., Ramachandran S., et al. Development of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation. Hum Immunol: 2010; 71 6 560 565
157. Bharat A., Saini D., Steward N., et al. Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg: 2010; 90 4 1094 1101
158. Otten H. G., van den Bosch J. M., van Ginkel W. G., van Loon M., van de Graaf E. A. Identification of non-HLA target antigens recognized after lung transplantation. J Heart Lung Transplant: 2006; 25 12 1425 1430
159. Saint Martin G. A., Reddy V. B., Garrity E. R., et al. Humoral (antibody-mediated) rejection in lung transplantation. J Heart Lung Transplant: 1996; 15 12 1217 1222
160. Magro C. M., Deng A., Pope-Harman A., et al. Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation: 2002; 74 9 1273 1280
161. Miller G. G., Destarac L., Zeevi A., et al. Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fluid. Am J Transplant: 2004; 4 8 1323 1330
162. Wallace W. D., Reed E. F., Ross D., Lassman C. R., Fishbein M. C. C4d staining of pulmonary allograft biopsies: an immunoperoxidase study. J Heart Lung Transplant: 2005; 24 10 1565 1570
163. Ionescu D. N., Girnita A. L., Zeevi A., et al. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl Immunol: 2005; 15 1 63 68
164. Girnita A. L., McCurry K. R., Yousem S. A., Pilewski J., Zeevi A. Antibody-mediated rejection in lung transplantation: case reports. Clin Transpl: 2006; 508 510
165. Magro C. M., Abbas A. E., Seilstad K., Pope-Harman A. L., Nadasdy T., Ross P. Jr. C3d and the septal microvasculature as a predictor of chronic lung allograft dysfunction. Hum Immunol: 2006; 67 4-5 274 283
166. Westall G. P., Snell G. I., McLean C., Kotsimbos T., Williams T., Magro C. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant: 2008; 27 7 722 728
167. Golocheikine A., Nath D. S., Basha H. I., et al. Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients. J Heart Lung Transplant: 2010; 29 4 410 416
168. Roberts D. M., Jiang S. H., Chadban S. J. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation: 2012; 94 8 775 783
169. Vo A. A., Lukovsky M., Toyoda M., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med: 2008; 359 3 242 251
170. Hachem R. R., Tiriveedhi V., Patterson G. A., Aloush A., Trulock E. P., Mohanakumar T. Antibodies to K-α 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant: 2012; 12 8 2164 2171
171. Lemy A., Toungouz M., Abramowicz D. Bortezomib: a new player in pre- and post-transplant desensitization? Nephrol Dial Transplant: 2010; 25 11 3480 3489
172. Woodle E. S., Alloway R. R., Girnita A. Proteasome inhibitor treatment of antibody-mediated allograft rejection. Curr Opin Organ Transplant: 2011; 16 4 434 438
173. Stegall M. D., Diwan T., Raghavaiah S., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant: 2011; 11 11 2405 2413